89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients - Concepedia

Concepedia

Publication | Closed Access

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

114

Citations

36

References

2014

Year

Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Sue Chua, Thijs H. Oude Munnink, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Mikhail Akimov, Cristina Fernandez‐Ibarra, Marjolijn N. Lub–de Hooge,

Clinical Cancer Research

Abstract

NVP-AUY922 showed proof-of-concept clinical response in HER2-amplified metastatic breast cancer. Early change on (89)Zr-trastuzumab PET was positively associated with change in size of individual lesions assessed by CT.

References

	Year	Citations

Page 1